0000899243-20-005685.txt : 20200224
0000899243-20-005685.hdr.sgml : 20200224
20200224210100
ACCESSION NUMBER: 0000899243-20-005685
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200220
FILED AS OF DATE: 20200224
DATE AS OF CHANGE: 20200224
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: North Michael Paul
CENTRAL INDEX KEY: 0001689925
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-24260
FILM NUMBER: 20646949
MAIL ADDRESS:
STREET 1: 3854 AMERICAN WAY, SUITE A
CITY: BATON ROUGE
STATE: LA
ZIP: 70816
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMEDISYS INC
CENTRAL INDEX KEY: 0000896262
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082]
IRS NUMBER: 113131700
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3854 AMERICAN WAY
STREET 2: SUITE A
CITY: BATON ROUGE
STATE: LA
ZIP: 70816
BUSINESS PHONE: 2252922031
MAIL ADDRESS:
STREET 1: 3854 AMERICAN WAY
STREET 2: SUITE A
CITY: BATON ROUGE
STATE: LA
ZIP: 70816
FORMER COMPANY:
FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP
DATE OF NAME CHANGE: 19940819
FORMER COMPANY:
FORMER CONFORMED NAME: M&N CAPITAL CORP
DATE OF NAME CHANGE: 19930125
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-20
0
0000896262
AMEDISYS INC
AMED
0001689925
North Michael Paul
3854 AMERICAN WAY, SUITE A
BATON ROUGE
LA
70816
0
1
0
0
Chief Information Officer
Common Stock
2020-02-20
4
F
0
130
194.12
D
9420
D
Common Stock
2020-02-21
4
M
0
5625
32.56
A
15045
D
Common Stock
2020-02-21
4
S
0
600
192.86
D
14445
D
Common Stock
2020-02-21
4
S
0
3435
193.87
D
11010
D
Common Stock
2020-02-21
4
S
0
1590
194.62
D
9420
D
Common Stock
2020-02-21
4
M
0
3788
46.35
A
13208
D
Common Stock
2020-02-21
4
S
0
441
192.84
D
12767
D
Common Stock
2020-02-21
4
S
0
2000
193.84
D
10767
D
Common Stock
2020-02-21
4
S
0
1347
194.57
D
9420
D
Common Stock
457
I
Through 401(k) Plan
Stock Option (right to buy)
32.56
2020-02-21
4
M
0
5625
0.00
D
2019-06-02
2025-06-02
Common Stock
5625
0
D
Stock Option (right to buy)
46.35
2020-02-21
4
M
0
3788
0.00
D
2018-01-20
2027-01-20
Common Stock
3788
1894
D
The total amount of shares beneficially owned includes 1,027 shares held in an employee stock purchase plan account.
These sales were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.40 to $193.32, inclusive. The reporting person undertakes to provide to Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.40 to $194.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.40 to $195.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.27 to $193.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.29 to $194.26, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.27 to $195.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (8) to this Form 4.
The information in this report is based on a plan statement dated as of December 31, 2019.
On January 20, 2017, the reporting person was granted an option to purchase 7,577 shares of common stock. The options are subject to time-based vesting conditions. 1,895 of the options vested on January 20, 2018, 1,894 of the options vested on January 20, 2019, 1,894 of the options vested on January 20, 2020, and 1,894 of the options will vest on January 20, 2021, provided that the reporting person remains continuously employed by the Issuer on such date, subject to prorated vesting provisions as provided in the award agreement for the stock options. The reporting person previously exercised 1,895 of the options.
/s/ Jennifer R. Guckert, pursuant to a power of attorney
2020-02-24